Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

MoonLake Immunotherapeutics Begins Sonelokimab Phase 2 trial In Hidradenitis Suppurativa (HS)

MoonLake Immunotherapeutics AG (NASDAQ:MLTX) dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis suppurativa (HS).

Initiation of this Phase 2 trial follows the approval of trial protocol obtained from the central Institutional Review Board, that supported IND filing with the regulatory agency.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.